CHEMICAL REVIEWS®



Correction to Hit Generation in TB Drug Discovery: From Genome to Granuloma

Tianao Yuan[®] and Nicole S. Sampson^{*®}

Chem. Rev. 2018, 118 (4), pp 1887-1916. DOI: 10.1021/acs.chemrev.7b00602

A few structural errors are noticed and listed as follows. A double bond was omitted in the original structure of imidazopyridine-1, TBA-7371, and Q203 in Figures 4, 7, and 8, respectively. The stereochemistry was not illustrated in the original structure of GSK-070 in Figure 8. The full structure of OPC-167832 was not demonstrated in Figure 8. All these errors have been corrected as shown below.




Figure 4. Hit compounds (A) identified in target-based whole-cell screens and (B) identified in whole-cell screen under growth culture conditions and discussed in the text. Also see Table 2.




Figure 7. Hit compounds identified in intracellular whole-cell screens against Mtb-infected macrophages and discussed in the text. Also see Table 2.




Figure 8. TB compounds identified in the screens outlined in Table 2 that are currently in clinical trials.

Published: May 6, 2019